Tag Archives: pharma

A Novel Tool to Meet Water Compliance and Quality Requirements in the Food and Beverage Industry

Here we propose a technology that offers a new suit of capabilities to support you in different challenges arising from meeting regulatory standards.

Discharge and Trucking Costs

Some of the areas of regulation that are proving hard to meet include the removal of pesticides, colour and hard to treat recalcitrant organics, especially at trace level. To treat regulatory compounds to levels acceptable for discharge can result in having to truck waste or absorb discharge fees. Finding means to treat waste on site and to higher standards with the right technology can help reduce cost. The Arvia ODC is very competitive to existing methods at removing trace level toxic organics on site to meet quality and regulatory standards for discharge to sewers.

Water Quality and Consistency

The need to ensure a high quality of raw materials is essential for production. This is particularly the case with water where the chemical composition of water supplied can vary in quality and purity. Water can have a major impact on the taste and flavour of products and therefore often requires further treatment. Arvia Technology’s Organic Destruction Cell (ODC) effectively removes micro-pollutants in potable water to ensure a purified and consistent standard for production. This includes the removal of pesticides, sweeteners and endocrine disruptors that are traditionally difficult and expensive to treat.

Recycling of Water

Increased water scarcity and hikes in water rates makes water reuse an attractive option to ease water dependency. Arvia Technology helps companies ease their water dependency by reducing the amount of RO reject water. The Arvia ODC works alongside Reverse Osmosis (RO) as a secondary process that is easy to fit into your current system. It can also be used to polish process water and waste water to improve water recycling rates.

Arvia Technology supports the Food and Beverage Industry by providing an environmentally friendly solution with no chemical additives or waste.

Come to our presentation ‘Optimising Water Usage in the Food and Beverage Industry’ on September 17th to find out more about this solution for improving your water cycle.


Dennis Curran, Product Management Director, BIOVIA

dennisDennis Curran is the Director of Product Management for BIOVIA and is focused on the integration of BIOVIA Software into customer solutions for scientific research. His direct product responsibilities include the BIOVIA Workbook and BIOVIA Laboratory Operations Suite. Since receiving his degree in Analytical Chemistry from Tufts University in 1985, Mr. Curran has been involved in the laboratory automation and software industries. His 30 years of career experience spans the scientific, engineering, software and management aspects of projects in the life sciences industry, from Drug Discovery through Development and Quality Control operations.

1. What are you looking forward to discussing with the audience?

So many pharmaceutical and biopharmaceutical organizations are increasing their focus on biotherapeutic drug development in order to remain competitive in the market. Unfortunately, this can backfire when these organizations don’t take in to account the resources required for managing the additional complex data and processes involved. This can increase exposure to compliance risk, decrease overall productivity and extend the time to market for new products. I’m excited to have the opportunity to show the audience that there is a better way to not only manage, but leverage biologics data by eliminating inefficient paper-based workflows, reducing the effort for creating experiments, providing better understanding of processes and products, and much more.

2. You’ve mentioned that the biologics R&D workflow is similar to small molecule R&D at the highest level but that there are differences in the details. Can you explain what changes as an organization shifts toward biotherapeutic development?

In short, biologic development demands unique processes due to the added complexity of biological systems. Compared to small molecule R&D, biologics workflows generate a large amount and a large variety of complex data. However, being able to distill the information and track the genealogy of how to get to an end entity is critical. This requires some advanced data and workflow management.

3. Why do you feel this topic is important?

In a recent market survey we conducted, we asked responders what percentage of their biopharmaceutical development processes are being supported with manual methods like pen/paper and/or Excel spreadsheets. To our surprise (and concern), we found that almost half of the responses indicated that at least 75% of their biologic development processes were supported by manual methods. The industry clearly needs to see that an electronic solution is available and can manage the end-to-end biologics workflow without the risk or hindrance of manual work.

4. What do you hope the audience will learn from this webinar?

By attending this webinar, I hope the audience will see the true potential impact of transitioning from a paper-based to an electronic Biologics solution covering all activities of the development process end to end and how that positively affects their bottom line.

Dennis will be presenting BIOVIA’s webinar ‘Building Better Biologics, Faster‘ on the 22nd July. Register here.

How many of these pharmaceutical wastewater issues are you addressing?

Integrated processes

‘End of pipe’ filtering is out. The new trend is to look at making water treatment an integrated part of process design. Since water recycling is currently less efficient for highly contaminated waste streams and those containing a diverse range of chemical properties, we believe the solution is to separate wastewater streams early in the process and destroy harmful pollutants near the source. Water that easy lends itself to recycling is separated from that which is less suitable. This would help ensure minimum effort and expense are required to deploy additional techniques in the process.

Water scarcity

Water is a precious resource. Only 3% of the Earth’s water is freshwater and more importantly less than 0.3% is available for use, with this use being split between the conflicting needs of public water supply and industry. Both for cost and environmental reasons, there is advantage in reducing water movement and contamination. The goal is often to maintain supply at the required quality level while controlling costs of transport, treatment and disposal. Regions with plentiful water supplies continue to use water in various processes and discharge it after use, but in regions suffering water scarcity every drop is valuable. How do you manage your water resources?


Alongside water scarcity, the viability of recycling both water and other materials is also a trending topic. We think cost and energy efficiency can be increased considerably by closing industrial water cycles as far as possible and identifying innovative materials for use. This subject is integral to our aims at Arvia. Arvia Technology is at the forefront of the sustainability revolution with our patented adsorbent material Nyex. Nyex is an adsorbent 3D electrode material used to separate contaminants from water so they can be eliminated with a low voltage electrical current. The Nyex is also cleaned in the process meaning it can be re-used continuously.

Changing parameters

The composition of process water is changing over time, especially in an area of high innovation such as pharmaceuticals. The Arvia process is flexible enough to treat a wide range of effluents and its modular construction makes it ideal for a changing landscape.

Environmental impact

Contaminants of emerging concern (CECs) in pharmaceutical wastes can have harmful effects on human health and aquatic life. Endocrine disrupters from medicines have been detected in drinking water and surface water, adversely affecting water quality. ‘Environmentally persistent pharmaceutical pollutants’ (EPPP) is a new emerging policy under consideration for the SAICM in 2015 http://www.saicm.org/index.php?option=com_content&view=article&id=452&Itemid=685 Are you feeling the pressure from the media as more stories come to light every day revealing the presence of dangerous pollutants in our rivers and lakes?

Related article:



How much do you spend on wastewater treatment and transport of wastewater? An internal review showed that Arvia Technology offers significant capital and operational expenditure savings in comparison with major treatment technologies for pharmaceutical organic wastes. A case study for a system that treats 10m3/day of pharmaceutical organic wastes of concentrations of 150 – 200 ppm shows that Arvia can achieve efficient treatment at a substantially lower OPEX per m3. Arvia Technology becomes the most cost effective (combined CAPEX and OPEX) after 4 months of operation, compared to reverse osmosis, activated carbon, advanced oxidation processes or trucking off site.

As the first water treatment process capable of destroying recalcitrant, stable organics and trace level pollutants without the use of chemicals, Arvia Technology can perform an important role in removing persistent micro-pollutants and emerging contaminants from those difficult waste streams. In an efficient water management system treated water can feed into the next process, but only once a reliable technology such as Arvia is in place to ensure it meets specific quality standards.

Come to Arvia’s presentation, ‘Pharma Wastewater Solutions: the next era of trace level organics removal’ on Wednesday 8th July to find out more about novel solutions to wastewater treatment.

Dr. Thomas P. Schoenknecht – Executive Director, Business Development. SHL Group

Thomas P. SchoenknechtThomas Schoenknecht has over 20 years’ experience in the pharmaceutical industry in various leading roles such as project management, research & development and business development. Before joining SHL in 2013, Thomas was head of global Key Account Organization at Schott Pharmaceutical Packing Division with a specific focus on new product developments addressing customer needs. Prior to Schott, Thomas worked at Amgen Inc California as Director of Drug Product and Device Development, where he oversaw and managed Amgen’s global drug delivery container projects and interfaced Amgen’s drug delivery device platforms. Finally, previous to Amgen, Thomas headed up the Research & Development activities at Gerresheimer’s Pharmaceutical Packing Division and was leading the Product Management and Business Development activities of this division for sterile drug delivery solutions.

Thomas has a Ph.D. in Biophysical Chemistry from the Max-Planck-Society and the University Goettingen, Germany and a Master’s degree in Chemistry from the University Goettingen. He is a frequent speaker, moderator and committee member at conferences regarding drug delivery and packing material science; Thomas was heading the PDA interest group for prefilled syringes and being active as member in various DIN ISO committees regarding primary packaging materials and drug delivery devices.

Thomas Schönknecht is currently an Executive Director, Business Development at SHL Group, responsible for global Business Development, Key Account Management and new Technology Evaluation within SHL’s Medical division.

  1.      Why did you decide to do a webinar with us?

Webinars offer an excellent platform for an open interactive exchange with our business partners regarding important topics driving our industry. As such, you need to find a provider who can offer an advanced platform and should be seen among the leading webinar providers with an excellent reputation to offer presentation content of interest to our targeted audience. After thorough evaluation, we are very happy to be working with Business Review Webinars, who can provide a robust platform and has been able to help us reach our targeted audience.

  1.       What will the audience gain from attending your webinar?

Devices for drug delivery are becoming a more vital factor for the success of a new drug being launched to the market or later during life cycle management. To have a successful device development program some few basic prerequisites need to be fulfilled – such as the selection of the drug container, HF studies, and final packaging. This webinar will highlight the most important ones and provide insight through real case studies on how a device development program should be planned and executed.

  1.       Who or what inspired you to get into the industry?

My interest for the pharmaceutical industry was first fostered and later induced through scientific work on my masters and later my Ph.D. thesis, where I analyzed the molecular structure of biomolecules that can become a target for new medical applications or even a new lead structure which can be converted later on into a new therapeutic. Working at the forefront, identifying new therapeutics and later establishing robust drug delivery solutions for these new drug substances gives you a good feeling, as you are working in a field where you help to make the life of people a little bit better.

  1.       What’s the most useful thing someone has ever taught you?

I had the opportunity to learn how to do research and development during my masters and Ph.D. time in the lab of Manfred Eigen, a Nobel laureate in Chemistry. The most valuable thing I gained from my scientific work and from him, was self-reflection and how to analyze given issues or challenges from different perspectives, which enables me to  identify the optimal solution for a given task based on a complete understanding of the problem at hand.

5.      Where would you recommend visiting in the world and why?

For me as a person having lived on various places and on different continents, every new place I am going to for business or vacation does reveal its own magic and beauty if you are open minded and willing to explore it without prejudice. However, if you are interested in device technology in addition, I can clearly recommend to visit Taiwan and our headquarter in Taoyuan near Taipei.

Dr. Thomas P. Schoenknecht will be presenting in SHL Group’s webinar ‘Prerequisites for a successful drug delivery device development program‘ on the 17th June at 3pm London/10am New York. You can register for the webinar here.

Nigel Brown: Founder, Inventor, Ideas man, Outdoor lover…

Nigel Brown2

Dr Nigel Brown is the Founder Director of Arvia Technology – a company based in north-west England which has patented an innovative method of removing micro-pollutants from water.

Dr Brown’s extensive scientific knowledge combined with practical experience make him one of the world’s leading authorities on the removal of micro pollutants from water and wastewater.

Trained in chemical engineering and environmental engineering, Dr Brown has had a far-reaching global career in the water industry which has included work in India, Canada, China, Italy and the US.

After university he spent 7 years as an international water and effluent troubleshooter for Foseco, ensuring the company fulfilled its obligations on  water treatment around the world. He then joined as Process Engineering Manager for Simon Hartley Limited, a company specialising in the manufacture and design of effluent plants and equipment. Later, as an independent consultant he specialised in water management and wastewater treatment – which sparked his interest in improving traditional methods of removing toxic chemicals.

The technology at the core of Arvia was developed at the University of Manchester, where Dr Brown, working with Dr Ted Roberts, was a research fellow in the department of Chemical Engineering and Analytical Science.


  1. What are you looking forward to explaining to the audience?

What I get excited about is the journey from initial research in my garage laboratory through academic research at the University of Manchester to the creation of Arvia Technology to exploit it. It is describing both how the technology works and the benefits that this can give to potential customers.

  1. Why did you decide to do a webinar with Business Review Webinars?

In our search for a webinar company to help us share our message, Business Review Webinars have shown to deliver a wide cross section of high quality and interested participants from across the globe.

  1. What has been the best moment in your career?

I think the best moment was the decision to go independent and work as a researcher and consultant. The ability to undertake my own research and find the means to support that was an exciting time. It was the initial stages of what was to become Arvia Technology.

  1. What’s the best book you’ve ever read and would recommend?

The Lord of the Rings has to be the best book I have ever read. The vastness of the storyline combined with the imagination and creativity. It is just epic!

  1. What motivates you?

To me it’s the application of knowledge. Taking all the research I do from an idea and being able to apply it to solve real problems. I like to sit on the academic and industrial interface and try to apply new ideas to solve problems.

6. Why are you particularly interested in the environmental side of things?

I particularly enjoy the outdoors so being able to address environmental issues is a real driver. The impact of humans on the environment is becoming increasingly significant, anything we can do to mitigate that is worthwhile.

7. What are you looking to achieve in the future in your personal and professional life?

In my professional life it is to see further large scale Arvia installations extending the process into disinfection, which is an exciting new development. Personally, the cost of getting the kids through university will be a major achievement.

8. How did you get into the industry and what do you most enjoy about your role?

By chance I worked with a company that assigned me a project in the water industry, which made me the company expert in this area. I was then given lots of other water problems to solve, which I very much enjoyed. The research side of the role is the most enjoyable. Being able to play in the lab is precious time, so it would be great to have more time to do that, but at this stage the main thing is to share what problems Arvia can already solve.

9. What has been your best holiday and where would you recommend visiting?

Victoria Falls in Zimbabwe. That was so fantastic I have been 3 times. You get drenched with the spray. As its so wet there is rainforest all around and the water creates an amazing mist.

10. What’s the most useful thing someone has taught you?

There is nothing stopping you pursuing your goals. Continue doing what you want to, until told otherwise. Senior Engineer I worked with in my first job called David Wilks.

Nigel will be presenting in Arvia’s webinar ‘Pharma Wastewater Solutions: the next era of trace level organics removal‘ on the 8th July at 3pm London/10am New York. You can register for the webinar here.

Piritta Maunu, Life Science Regulatory Expert, Vaisala

Piritta MaunuPiritta Maunu is a Life Science Regulatory Expert in Vaisala. She has long experience in biotechnology, having worked in several quality management positions in R&D, quality and GMP production. Piritta holds a degree of M.Sc. (Cell Biology) and has studied teaching with a specialty in General Biology. In her role at Vaisala, she creates informational content for life science customers and provides application support to R&D teams creating solutions for monitoring critical environments. Additionally, she provides training through webinars and seminars to both internal groups at Vaisala and to industry contacts.

1. Why did you decide to do a webinar with Business Review Webinars?

Through webinars we want to share the vast amount of knowledge that Vaisala experts have about measurement and monitoring of regulated environments. Business Review Webinars have proven to be a good platform for reaching out to the different players in the life science industry.

2. What are you looking forward to explaining to the audience?

I will discuss the chain of actions you need to understand and perform when storing supplies and products in warehouses regulated by Good Distribution Practices (GDP). These regulations tell you to perform a mapping study before storing any products in the storage areas. However, they don’t necessarily give you any practical guidance. In the webinar we go through some reference documents explaining what should be done as part of a mapping study. I will also give some advice on how to select the locations of sensors or data loggers for a monitoring system, and how the changes in the Annex 15 affect your mapping qualification and monitoring system software validation work. And last but not least, I will discuss some simple risk assessment principles that should provide help in validation of a monitoring system software.

3. What do you most enjoy about your role?

I enjoy working as a regulatory expert and meeting professionals within the field of life science. As I also have a degree in teaching biology, I find teaching people new skills very rewarding.

4. What would someone be surprised to know about you?

I studied music before taking my degree in cellular biology and teaching. During that time I played traditional Finnish instrument called “kantele” (it is similar to zither) as well as harp. The musical conservatory was located quite far away from my home, so I used to drive there by motorbike. My friends called me the motorcycling harpist.

5. What do you do in your leisure time to relax?

I like sports, as well as hiking and observing the wonders of the nature. I also enjoy fishing and picking berries. As my kids play soccer, it is part of my leisure time as well – watching the games and travelling around the country for the tournaments.

Piritta will be presenting Vaisala’s webinar ‘The Impact of 2015 Revisions to EU GMP Annex 15 on GDP’ on the 25th June at 3pm London/10am New York. You can register for the webinar here.

Bend Research (a division of Capsugel Dosage Form Solutions): Jeff Breit, Director & Brandon Downey, Technical Group Leader


Jeff Breit & Brandon Downey will describe efforts at Bend Research to develop integrated biotherapeutic manufacturing hardware and software technologies to reduce risk and optimize their clients’ fed-batch and perfusion processes. Register here.


1. Why did you decide to do a webinar with us?

We spent some time evaluating webinar vendors and felt that Business Review Webinars offered the right audience for our content, as well as an advanced platform designed to engage the audience.

Response from Phoenix Barringer, Marketing Manager at Bend Research, a division of Capsugel Dosage Form Solutions

2. What are you looking forward to explaining to the audience? 

We are currently developing a bioprocess definition platform based on a fundamental understanding of input/output relationships and system dynamics.  This platform is enabled by an integrated laboratory setting, which contains automated sampling handling hardware combined with PAT technology and large data set reduction software tools.  A case study will be presented that highlights the capabilities of the lab and a bioprocess development methodology that focuses on increasing product quality and streamlining the product development critical path.

Response from Jeff Breit, Director at Bend Research, a division of Capsugel Dosage Form Solutions

3. How did you get into the industry?

Bend Research has a track record of scientific and engineering excellence in the pharmaceutical development space.  Our clients requested that we leverage our engineering and biological expertise to better understand and consider optimizing practices in biologics manufacturing.  Since venturing into this space approximately 8 years ago, we have advanced certain technologies, often with development partners, in order to streamline and ensure direct application in upstream and downstream manufacturing practices.  Recently, we have focused our efforts on integration, data reduction and prediction, as these capabilities and technologies are needed to advance next generation processes in fed batch, perfusion and continuous manufacturing.

Response from Jeff Breit, Director at Bend Research, a division of Capsugel Dosage Form Solutions

4. Why are cell response dynamics important for developing a feed or control strategy in a bioreactor?

We are using cell responses to generate the right kind of data to build a predictive model showing how the inputs, like feeds, affect the outputs, such as titer and product quality. A predictive model of this type can help to develop a feeding strategy through predictive optimization, and by increasing process understanding of how the selected inputs affect the product outputs. A predictive model can also be used in a model predictive controller for active control of product outputs.

Response from Brandon Downey, Technical Group Leader at Bend Research, a division of Capsugel Dosage Form Solutions

5. In regards to PAT integration in your lab, how are your selecting analytical tools and how are you using the data sets that are produced?

Analytical tools measure the product outputs that are important from a quality perspective. Essentially, whatever needs to be controlled should be measured. The most important product quality measurements may vary from product to product, but the underlying methodology is the same.

Response from Brandon Downey, Technical Group Leader at Bend Research, a division of Capsugel Dosage Form Solutions

Join Jeff & Brandon in Bend Research’s webinar ‘Innovative, PAT-Integrated Bioprocess Environment’ on 3 June at 4pm London/11am New York.

Is Innovation the Key to a Single-Use TFF Future?

Parker Webinar

Advances in technology are allowing biomanufacturers to move to entirely single-use set-ups for tangential flow filtration and benefit from the many advantages of single-use technology. Tangential flow filtration (TFF) is a common operation in the manufacture of biopharmaceuticals and has traditionally been performed using reusable cross flow filters installed in stainless steel systems. Innovations in single-use technology can bring many benefits to biopharmaceutical TFF operations.

TFF applications in bioprocessing

Tangential flow filtration applications are typically divided into microfiltration or ultrafiltration applications depending on the cut-off of the membrane used. Microfiltration is often used to effect solid-liquid separation, such as the clarification of E.coli lysates or even mammalian cells. Ultrafiltration is more commonly associated with the concentration and diafiltration of soluble biopharmaceutical products, such as recombinant proteins and monoclonal antibodies, either during their purification or at the end of the purification process to prepare the product for filling operations.

Drivers for switching to single-use setups for TFF operations

1. The solutions and steam required for cleaning and sterilizing reusable filters and systems need to be generated by installing dedicated equipment with a capital and running cost.

2. Validation of the steaming and cleaning regimes takes time and delays the speed with which new biopharmaceutical products reach the market.

3. There is a risk of product cross contamination in multi-product facilities because, even if the filters are dedicated to a particular product, the equipment itself is unlikely to be.

4. Stainless steel systems are inflexible and difficult to modify. This is especially a problem during the development of the process when optimum configurations are being identified, but it can also represent a challenge post-approval if continuous improvement activities identify configuration optimization opportunities.

Innovations in technology are now allowing biomanufacturers to switch from stainless steel TFF operations, and their associated challenges, to entirely single-use set-ups.

Innovations in single-use technology

1. Single-use, gamma-irradiatable TFF filters

2. Pilot and 21 CFR Part 11 compliant single-use automated systems

3. Fully disposable fluid flow paths

4. Single-use sensors for measuring critical processing parameters

Single-use automated TFF solutions are fully scaleable from lab to GMP manufacturing and increase flexibility during process development, delivering more optimized processes. With reduced assembly, set-up and tear down time, manufacturing productivity is enhanced while capital investment in utilities, plant and time to market is reduced. Importantly, these benefits can be achieved while increasing quality through minimizing cross contamination risks, delivering a higher level of control and standardizing the operators’ experience.

To learn more, register here for Parker’s webinar.

This post was contributed by Nick Hutchinson, Market Development Manager (Pharma & Biotech) at Parker domnick hunter Process Filtration, UK.

Parker domnick hunter, specializes in automating and controlling single-use processes. By integrating sensory and automation technology into a process, a manufacturer can control the fluid flow more effectively, ensuring the quality of the final product. Find out more about Parker domnick hunter’s single-use TFF solutions.

Gene Tetreault, Sr. Director, Products and Marketing for the Laboratory Informatics Portfolio

Gene LI

In this role Gene is providing the vision, strategy and management of the laboratory informatics product portfolio that includes the Electronic Laboratory Notebook, Laboratory Information Management System and the Laboratory Execution system.

Gene has been working in the Life Science industry for over 20 years developing robotic and Laboratory informatics systems.


 1. What are you looking forward to discussing with the audience?

The focus of our discussion will be the typical challenges that come along with paper based and/or disconnected processes in the Quality Testing context. We will give an overview of the possibilities and capabilities of the BIOVIA Quality Testing solution and show the benefits of moving to an electronic Quality Testing solution. We will also analyze how they can tie into contributing to the overall goals of an organization.

2. You’ve mentioned that quality operations are typically a bottleneck and considered to include many non-value add activities for the drug manufacturing process. Can you explain why?

Studies at drug manufacturing companies have shown that the average time for Quality Control/Quality Assurance activities is typically almost double the time an organization spends on actual production processes. This is largely due to organizations relying on paper based and disconnected processes which are difficult to manage and make adherence to regulations more challenging and resource consuming. In addition, many quality testing systems are not integrated with an inventory solution making even more manual data entry work. These inefficiencies lead to non-value add waiting times for the release of raw materials used in the production process as well as to waiting and high inventory costs by a delayed release of finished products.

3. Is this topic only relevant for roles that are directly engaged in working with Quality Testing?

Quality Testing should actually be seen in the larger context of an organization’s Total Quality Strategy. Many capabilities play into the successful management and execution of Quality. This includes for example, the definition, documentation, submission, monitoring and management of quality related activities and tasks as well as the execution of quality tests. The BIOVIA approach will support the FDA mandate for deeper integration of Quality into end-to-end operations to design quality into products and processes as well as foster a quality culture across all areas of an organization from discovery to commercialization.

4. What do you hope the audience will learn from this webinar?

By attending this webinar, I hope the audience will see the true potential impact of eliminating paper from their Quality Testing processes and how that positively affects their bottom line.

Join Gene Tetreault in BIOVIA’s Webinar ‘Building Compliance and Operational Excellence into your Quality Lab Operations’ on 19 May at 4pm London/11am New York

Seamless innovation by improved laboratory informatics

OSTHUS Webinar

Life science data is a major asset for biopharmaceutical and chemical industries. Their availability via electronic systems is a prerequisite for collaborative work and successful innovation.  Currently, most laboratories have to deal with a multitude of data sources originating from different instruments, systems, sites and external resources all with their own data formats. As a consequence, scientists often have to do a lot of manual effort to gain access to the data they need and IT teams are struggling to maintain the large amounts of different IT solutions.  Data analytics becomes an inefficient process with a high amount of integration effort.

Typically data integration of life science data is very time consuming. So why is it so time consuming? Data integration projects are complex because you combine data from multiple data sources and these often have different data standards, different data formats, different semantics and different data quality.  Data integration is characterized by a high degree of exception handling. Typographical errors caused at data entry, fuzzy definitions of concepts, or inconsistent interpretation of data by different informatics systems are typical root causes. To integrate data efficiently you need to have in depth knowledge of both IT and the science –  a combination which is quite rare.  So what can you do if you don’t have these people readily available?

One way to make these integration projects go smoother is using reference architectures and data standards. We will show several uses cases to illustrate how reference architectures can support you in data integration, data curation & data migration. One of these reference architectures addresses the migration of biopharmaceutical data using an integration layer on top of a data warehouse as part of a discovery data integration process. This architecture was used in a data integration project combining multiple heterogeneous data sources, all with different data formats and standards.






Central in this architecture is a data curation platform – the operation data store – which provides an easy to use easy-to-use entry to scientific data management and can be used by non-IT experts giving your scientific data experts control of the data integration. During the webinar we will show you additional reference architectures and will highlight how data standards can help you in tackling these complicated projects.

So do you recognize these problems? Is your company dealing with a myriad of data sources or are you losing too much time connecting data? Join us for this webinar in which we will show you how data integration projects can be made easy.

Register here for OSTHUS Webinar.

For more information on our company and services visit www.osthus.com or contact us at [email protected]